Verrica Pharmaceuticals reported a Q4 basic EPS loss of US$0.57, despite revenue growth throughout 2025, leading to renewed debate on its path to sustainable profitability. The company’s trailing twelve-month revenue was US$35.6 million with a net loss of US$17.9 million, highlighting that increased sales have not yet offset operating costs. While growth forecasts are strong, concerns remain over deepening losses, a short cash runway, and shareholder dilution.
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability
Verrica Pharmaceuticals reported a Q4 basic EPS loss of US$0.57, despite revenue growth throughout 2025, leading to renewed debate on its path to sustainable profitability. The company’s trailing twelve-month revenue was US$35.6 million with a net loss of US$17.9 million, highlighting that increased sales have not yet offset operating costs. While growth forecasts are strong, concerns remain over deepening losses, a short cash runway, and shareholder dilution.